MX2019015508A - Nanopartículas para el tratamiento del cáncer. - Google Patents

Nanopartículas para el tratamiento del cáncer.

Info

Publication number
MX2019015508A
MX2019015508A MX2019015508A MX2019015508A MX2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A
Authority
MX
Mexico
Prior art keywords
nanoparticles
treating cancer
cells
preparation
breast cancer
Prior art date
Application number
MX2019015508A
Other languages
English (en)
Inventor
Navarro Adrian Daneri
Camacho Antonio Topete
Escareño Abraham Noé Rosas
Original Assignee
Univ Guadalajara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Guadalajara filed Critical Univ Guadalajara
Priority to MX2019015508A priority Critical patent/MX2019015508A/es
Priority to EP20901619.5A priority patent/EP4101471A4/en
Priority to PCT/IB2020/061716 priority patent/WO2021124028A1/es
Priority to US17/787,791 priority patent/US20230285457A1/en
Publication of MX2019015508A publication Critical patent/MX2019015508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención está relacionada con nanopartículas fotoresponsivas de liberación estimulada y su uso como una nueva estrategia para proveer un tratamiento antitumoral para cáncer de mama con especificidad incrementada. Se describen células Natural Killer (NK) con gránulos citotóxicos cargados de las nanopartículas fotoresponsivas de liberación estimulada biocompatibles, así como métodos para su preparación.
MX2019015508A 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer. MX2019015508A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2019015508A MX2019015508A (es) 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer.
EP20901619.5A EP4101471A4 (en) 2019-12-18 2020-12-09 NANOPARTICLES FOR CANCER TREATMENT
PCT/IB2020/061716 WO2021124028A1 (es) 2019-12-18 2020-12-09 Nanopartículas para el tratamiento del cáncer
US17/787,791 US20230285457A1 (en) 2019-12-18 2020-12-09 Nanoparticles for cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019015508A MX2019015508A (es) 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer.

Publications (1)

Publication Number Publication Date
MX2019015508A true MX2019015508A (es) 2021-06-21

Family

ID=76478260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015508A MX2019015508A (es) 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer.

Country Status (4)

Country Link
US (1) US20230285457A1 (es)
EP (1) EP4101471A4 (es)
MX (1) MX2019015508A (es)
WO (1) WO2021124028A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115152750B (zh) * 2022-07-16 2024-01-26 杭州星空男孩新材料科技有限公司 一种长效抗菌喷雾剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999161B2 (en) 2005-01-22 2011-08-16 Alexander Oraevsky Laser-activated nanothermolysis of cells
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN104688773B (zh) 2005-10-26 2017-11-03 Toto株式会社 杀细胞剂
EP2398466B1 (en) 2008-11-24 2021-02-17 Massachusetts Institute of Technology Methods and compositions for localized nanoparticle delivery to a tumor
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US8664198B2 (en) 2011-02-28 2014-03-04 The University Of Central Oklahoma Immunologically modified carbon nanotubes for cancer treatment
PL2508207T3 (pl) 2011-03-31 2013-09-30 Bioalliance Pharma Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy
WO2012142669A1 (en) 2011-04-20 2012-10-26 The University Of Sydney A method for the treatment of a solid tumour
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
MX2015012920A (es) 2013-03-14 2016-06-02 Univ Johns Hopkins Celulas presentadoras de antígeno artificial de nanoescala.
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
US10835605B2 (en) * 2015-10-01 2020-11-17 University Of South Carolina Preparations of poly(lactic-co-glycolic acid)/polydopamine core/shell hybrid nanoparticle for photothermal applications

Also Published As

Publication number Publication date
EP4101471A4 (en) 2024-01-10
EP4101471A1 (en) 2022-12-14
WO2021124028A1 (es) 2021-06-24
US20230285457A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020006015A (es) Composiciones y procedimientos para inhibir el agotamiento de celulas t.
PH12019501959A1 (en) Therapeutic rna
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
NZ739133A (en) Cellular targeted active ingredient delivery system
PH12017501420A1 (en) Compositions and methods of tumor treatment utilizing nanoparticles
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2014014361A (es) Anticuerpos anti-egfr y usos de los mismos.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2020001727A (es) Terapia de combinacion.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MY200161A (en) Bacteria for targeting tumors and treating cancer
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
NZ625758A (en) Method for treating breast cancer
MX2019015508A (es) Nanopartículas para el tratamiento del cáncer.
WO2018193476A3 (en) ANTICANCER COMPOUNDS
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MY194488A (en) Syd985 treatment of t-dm1 refractory cancer patients